Although inhibitors like SB290157 have demonstrated protection against kidney inflammation and fibrosis by blocking C3aR function (82), their clinical application is limited by findings that SB290157 may act as an agonist for both C3aR and C5aR2 (83). This evidence concerns the gene C3AR1 and urogenital neoplasm.